注射部位结节与每周一次皮下注射西马鲁肽有关。

Q3 Medicine

Diabetes Spectrum Pub Date : 2021-01-01 DOI:10.2337/ds20-0033

Elizabeth B Hearn, Justin J Sherman

{"title":"注射部位结节与每周一次皮下注射西马鲁肽有关。","authors":"Elizabeth B Hearn, Justin J Sherman","doi":"10.2337/ds20-0033","DOIUrl":null,"url":null,"abstract":"Glucagon-like peptide 1 (GLP-1) receptor agonists are a safe and effective treatment option for patients with type 2 diabetes (1). Selective activation of the GLP-1 receptor causes glucose-dependent insulin secretion, resulting in a very low risk of hypoglycemia (2). The additional mechanism of slowing gastric emptying has resulted in reliable weight loss with this class of antihyperglycemic medications (3). In addition, multiple agents in this drug class (semaglutide, liraglutide, and dulaglutide) have been proven to reduce the risk of cardiovascular events (4).","PeriodicalId":39737,"journal":{"name":"Diabetes Spectrum","volume":" ","pages":"73-75"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7887535/pdf/diaspectds200033.pdf","citationCount":"2","resultStr":"{\"title\":\"Injection-Site Nodules Associated With Once-Weekly Subcutaneous Administration of Semaglutide.\",\"authors\":\"Elizabeth B Hearn, Justin J Sherman\",\"doi\":\"10.2337/ds20-0033\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Glucagon-like peptide 1 (GLP-1) receptor agonists are a safe and effective treatment option for patients with type 2 diabetes (1). Selective activation of the GLP-1 receptor causes glucose-dependent insulin secretion, resulting in a very low risk of hypoglycemia (2). The additional mechanism of slowing gastric emptying has resulted in reliable weight loss with this class of antihyperglycemic medications (3). In addition, multiple agents in this drug class (semaglutide, liraglutide, and dulaglutide) have been proven to reduce the risk of cardiovascular events (4).\",\"PeriodicalId\":39737,\"journal\":{\"name\":\"Diabetes Spectrum\",\"volume\":\" \",\"pages\":\"73-75\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7887535/pdf/diaspectds200033.pdf\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes Spectrum\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2337/ds20-0033\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes Spectrum","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2337/ds20-0033","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 2

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Injection-Site Nodules Associated With Once-Weekly Subcutaneous Administration of Semaglutide.

Glucagon-like peptide 1 (GLP-1) receptor agonists are a safe and effective treatment option for patients with type 2 diabetes (1). Selective activation of the GLP-1 receptor causes glucose-dependent insulin secretion, resulting in a very low risk of hypoglycemia (2). The additional mechanism of slowing gastric emptying has resulted in reliable weight loss with this class of antihyperglycemic medications (3). In addition, multiple agents in this drug class (semaglutide, liraglutide, and dulaglutide) have been proven to reduce the risk of cardiovascular events (4).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Diabetes Spectrum Medicine-Internal Medicine

CiteScore

2.70

自引率

0.00%

发文量

期刊介绍： The mission of Diabetes Spectrum: From Research to Practice is to assist health care professionals in the development of strategies to individualize treatment and diabetes self-management education for improved quality of life and diabetes control. These goals are achieved by presenting review as well as original, peer-reviewed articles on topics in clinical diabetes management, professional and patient education, nutrition, behavioral science and counseling, educational program development, and advocacy. In each issue, the FROM RESEARCH TO PRACTICE section explores, in depth, a diabetes care topic and provides practical application of current research findings.